NK细胞大颗粒淋巴细胞白血病的诊断标准:通过一项多中心国际研究验证
该多中心国际研究在来自美国、意大利和法国3个国家登记处的独立训练队列(n=78)和验证队列(n=57)中,修订并验证了整合NK细胞评分、CCL22突变和骨髓活检(BMB)结果的NK-LGLL诊断标准。修订后的框架提高了诊断敏感性且未降低特异性,可能减少对侵入性操作的依赖。
要点
- 修订标准纳入4项主要标准:NK细胞计数≥1.0×10^9/L、KIR限制、CD94/NKG2A过表达及STAT3/TET2/CCL22突变。
- 训练队列中CCL22突变见于16例(20%),其中5例中间评分患者被重新分类为NK-LGLL。
- 验证队列中CCL22突变见于5例NK-LGLL(20%)。
核心结论
- 整合CCL22突变减少了未分类患者的比例,提高了诊断敏感性且未降低特异性,可能减少对侵入性操作的依赖。
- 这些修订的国际标准代表了向标准化、分子指导的NK-LGLL诊断迈出的一步。
研究设计与样本
- 多中心国际研究,使用来自美国、意大利和法国3个国家登记处的独立训练队列(n=78)和验证队列(n=57)对修订后的诊断标准进行验证。
主要发现
- 训练队列中50例患者因NK评分>4被分类为NK-LGLL,18例为中间评分(2-3),10例诊断为反应性增殖。
- 训练队列中CCL22突变见于16例患者(20%),包括5例中间评分患者被重新分类为NK-LGLL;BMB在另外2例中支持诊断,最终共57例NK-LGLL。
- 这些NK-LGLL患者比替代诊断患者表现出更多的血细胞减少、更高的治疗需求和更大的输血需求。
- 验证队列(25例NK-LGLL和32例反应性病例)中,CCL22突变见于5例NK-LGLL(20%)。
关键数值与推荐
- 定义了4项主要标准:NK细胞计数≥1.0×10^9/L、杀伤细胞免疫球蛋白样受体限制、CD94/NKG2A过表达,以及STAT3、TET2或CCL22的体细胞突变(后者为新引入)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Natural killer (NK) large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder lacking definitive clonality markers, complicating diagnosis and distinction from reactive NK cell expansions. We previously proposed an NK clonality score with high diagnostic accuracy, but a subset of patients remained unclassified. In this multicenter international study, we refined and validated updated diagnostic criteria using independent training (n = 78) and validation (n = 57) cohorts from 3 national registries (United States, Italy, and France). The revised framework integrates NK score parameters with CC motif chemokine ligand 22 (CCL22) mutations and bone marrow biopsy (BMB) findings. Four major criteria were defined: NK cell count of ≥1.0 × 109/L, killer-cell immunoglobulin-like receptor restriction, CD94/NKG2A overexpression, and somatic mutations in STAT3, TET2, or CCL22, the latter newly introduced. In the training cohort, 50 patients were classified as having NK-LGLL by an NK score of >4, 18 had intermediate scores (2-3), and 10 were diagnosed as reactive proliferations. CCL22 mutations were identified in 16 patients (20%), including 5 with intermediate scores who were reclassified as NK-LGLL; BMB supported the diagnosis in 2 additional cases, resulting in 57 NK-LGLL overall. These patients exhibited more cytopenias, higher treatment needs, and greater transfusion requirements than patients with alternative diagnoses. In the validation cohort (25 NK-LGLL and 32 reactive cases), CCL22 mutations were detected in 5 NK-LGLL (20%). Altogether, incorporation of CCL22 mutations reduced the fraction of unclassified patients, improved diagnostic sensitivity without compromising specificity, and may decrease reliance on invasive procedures. These revised international criteria represent a step toward standardized, molecularly guided NK-LGLL diagnosis.
引用
- Pastoret C, Yang J, Feith DJ, et al. Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study. Blood Adv. 2026. PMID: 41191533. doi:10.1182/bloodadvances.2025016509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。